• Mashup Score: 2

    HealthTree Coach, Steve Hodges, shares his AML story and why he decided to become a Coach.

    Tweet Tweets with this article
    • Feeling inspired today by the remarkable story of a beloved @DukeHMCT patient w/#AML who is doing so much to teach and give back to the community, now as a coach for @HealthTreeAML. Read his #leukemia and transplant story here: https://t.co/Wb1wrwulvT #leusm #bmtsm @DukeCancer

  • Mashup Score: 0

    The content provided in this page is to help address the often difficult topics of hospice and palliative care. Content contributions were made by Steve Hodges.

    Tweet Tweets with this article
    • He also shares poignant insights on the importance of #palliativecare, and sometimes #hospice, as part of the #AML journey. Thank you @HealthTreeAML for making great use of our interview here too! https://t.co/gV7SL56APM #leusm #bmtsm #hapc #leukemia @DukeCancer @DukeHMCT

  • Mashup Score: 5

    A retrospective analysis of more than 17,000 patients with hematologic malignancies identified a difference in median survival between patients who received palliative care in addition to hematopoietic stem cell transplantation and those who didn’t.

    Tweet Tweets with this article
    • Evidence continues to show that integrated #palliative care is better care, even along w/ aggressive curative-intent cancer treatments: "Palliative Care in HSCT Correlates With Longer Survival in Hematologic Cancers" https://t.co/BgKQhZQ2Le via @CancerNetwrk #bmtsm #hapc #ASCO23

  • Mashup Score: 0

    AuthorsMatthew Joseph WieduwiltAtrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NCMatthew Joseph Wieduwilt, Jun Yin, Oudom Kour, Rebecca Teske, Wendy Stock, Kenneth Byrd, Kimberley Doucette, James Mangan, Gregory A. Masters, Alice S. Mims, Katarzyna Jamieson, Shira Naomi Dinner, Ali W. Bseiso, Geoffrey L. Uy, Harry Paul Erba, Mark Robert Litzow, Richard M….

    Tweet Tweets with this article
    • Coming up shortly: chemotherapy-free treatment of newly-diagnosed Ph-negative CD22+ B-cell ALL with blinatumomab and inotuzumab. Would love to kick chemo to the curb in leukemia care! Important study https://t.co/9Gf2GSflt8 #ASCO23 #leusm